Resilience Announces Long-Term Financing of up to $825 Million to Accelerate CDMO Strategy
New Capital from Oak Hill Advisors to Drive Investment in Go-Forward Manufacturing Operations CINCINNATI--(BUSINESS WIRE)--National Resilience...
New Capital from Oak Hill Advisors to Drive Investment in Go-Forward Manufacturing Operations CINCINNATI--(BUSINESS WIRE)--National Resilience...
A Q&A with Nithin Stephen As the pharmaceutical and biotech industries continue to innovate at a rapid pace, the demand for fill/finish capabilities...
Biomanufacturing safety and efficacy depend on well-controlled, compliant manufacturing processes. Can a virtual model truly give biomanufacturing...
Are you an innovator company looking for a reliable and innovative partner? You have come to the right place.
Resilience and Pluristyx have entered a strategic collaboration to accelerate and simplify the transition of promising iPSC-derived therapies from...
The proliferation of recombinant protein therapies has driven the need for new capacity in the biotherapeutic manufacturing space. Monoclonal...
How Early-Phase Companies Can Future-Proof Their Cell Therapies The following was extracted from a conversation with Eytan Abraham “Q: How should...
Resilience is proud to announce the official opening of our West Coast (San Diego, CA) Cell Therapy PAD center. This location will serve as our...